Indeed, a recent report by Nose and colleagues reported that in patients with advanced gastric cancer, those with a high frequency of CD8+ PD-1+CD103+ T cells in peripheral blood two weeks after the start of treatment had significantly better response to immune checkpoint inhibition and better progression-free survival36. The gene discussed is CD8A; the disease is gastric cancer.